参考文献/References:
[1] Marshall SM. Diabetic nephropathy in type 1 diabetes: has the outlook improved since the 1980s[J]Diabetologia,2012,55(9):2301-2306. DOI: 10.1007/s00125-012-2606-1.
[2] Krolewski AS, Bonventre JV. High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline[J].Semin Nephrol,2012,32(5):407-414. DOI: 10.1016/j.semnephrol.2012.07.002.
[3] Hovind P, Rossing P, Tarnow L,et al. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study[J].Diabetes,2009,58(7):1668-1671. DOI: 10.2337/db09-0014.
[4] Jalal DI, Rivard CJ, Johnson RJ,et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study[J].Nephrol Dial Transplant,2010,25(6):1865-1869.DOI: 10.1093/ndt/gfp740.
[5] Ficociello LH, Rosolowsky ET, Niewczas MA,et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up[J].Diabetes Care,2010,33(6):1337-1343. DOI: 10.2337/dc10-0227.
[6] Krolewski AS, Niewczas MA, Skupien J,et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria[J].Diabetes Care,2014,37(1):226-234.DOI: 10.2337/dc13-0985.
[7] Miao Y, Ottenbros SA, Laverman GD,et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin Ⅱ Antagonist Losartan Trial[J].Hypertension,2011,58(1):2-7.DOI: 10.1161/HYPERTENSIONAHA.111.171488.
[8] Zoppini G, Targher G, Chonchol M,et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function[J].Diabetes Care,2012,35(1):99-104. DOI: 10.2337/dc11-1346.
[9] Kim WJ, Kim SS, Bae MJ,et al. High-normal serum uric acid predicts the development of chronic kidney disease in patients with type 2 diabetes mellitus and preserved kidney function[J].J Diabetes Complications,2014,28(2):130-134. DOI: 10.1016/j.jdiacomp.2013.11.006.
[10] Tanaka K, Hara S, Hattori M,et al. Role of elevated serum uric acid levels at the onset of overt nephropathy in the risk for renal function decline in patients with type 2 diabetes[J].J Diabetes Investig,2015,6(1):98-104. DOI: 10.1111/jdi.12243.
[11] Samant P, Chavan P. Brachial artery flow mediated vasodilatation changes in endothelium due to hyperuricemia in type 2 diabetes mellitus [J]. Br Med Med Res, 2014, 4(1): 441-450.
[12] Oberbach A, Neuhaus J, Jehmlich N,et al. A global proteome approach in uric acid stimulated human aortic endothelial cells revealed regulation of multiple major cellular pathways[J].Int J Cardiol,2014,176(3):746-752. DOI: 10.1016/j.ijcard.2014.07.102.
[13] Hong Q, Qi K, Feng Z,et al. Hyperuricemia induces endothelial dysfunction via mitochondrial Na+/Ca2+ exchanger-mediated mitochondrial calcium overload[J].Cell Calcium,2012,51(5):402-410. DOI: 10.1016/j.ceca.2012.01.003.
[14] Choi YJ, Yoon Y, Lee KY,et al. Uric acid induces endothelial dysfunction by vascular insulin resistance associated with theimpairment of nitric oxide synthesis[J].FASEB J,2014,28(7):3197-3204. DOI: 10.1096/fj.13-247148.
[15] Feig DI, Madero M, Jalal DI,et al. Uric acid and the origins of hypertension[J].J Pediatr,2013,162(5):896-902. DOI: 10.1016/j.jpeds.2012.12.078.
[16] Johnson RJ, Lanaspa MA, Gabriela Sánchez-Lozada L,et al. The discovery of hypertension: evolving views on the role of the kidneys, and current hot topics[J].Am J Physiol Renal Physiol,2015,308(3):F167-F178. DOI: 10.1152/ajprenal.00503.2014.
[17] Zhang JX, Zhang YP, Wu QN,et al. Uric acid induces oxidative stress via an activation of the renin-angiotensin system in 3T3-L1 adipocytes[J].Endocrine,2015,48(1):135-142. DOI: 10.1007/s12020-014-0239-5.
[18] Kushiyama A, Okubo H, Sakoda H,et al. Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development[J].Arterioscler Thromb Vasc Biol,2012,32(2):291-298. DOI: 10.1161/ATVBAHA.111.234559.
[19] Nomura J, Busso N, Ives A,et al. Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK[J].PLoS One,2013,8(9):e75527. DOI: 10.1371/journal.pone.0075527. eCollection 2013.
[20] Fan CY, Wang MX, Ge CX,et al. Betaine supplementation protects against high-fructose-induced renal injury in rats[J].J Nutr Biochem,2014,25(3):353-362. DOI: 10.1016/j.jnutbio.2013.11.010.
[21] Wang MX, Liu YL, Yang Y,et al. Nuciferine restores potassium oxonate-induced hyperuricemia and kidney inflammation in mice[J].Eur J Pharmacol,2015,747:59-70. DOI: 10.1016/j.ejphar.2014.11.035.
[22] Lanaspa MA, Ishimoto T, Cicerchi C,et al. Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy[J].J Am Soc Nephrol,2014,25(11):2526-2538. DOI: 10.1681/ASN.2013080901.
[23] Zhang J, Xiang G, Xiang L,et al. Serum uric acid is associated with arterial stiffness in men with newly diagnosed type 2 diabetes mellitus[J].J Endocrinol Invest, 2014,37(5):441-447.DOI: 10.1007/s40618-013-0034-9.
[24] Sheikhbahaei S, Fotouhi A, Hafezi-Nejad N,et al. Serum uric acid, the metabolic syndrome, and the risk of chronic kidney disease in patients with type 2 diabetes[J].Metab Syndr Relat Disord,2014,12(2):102-109. DOI: 10.1089/met.2013.0119.
[25] 中华医学会风湿病学分会. 原发性痛风诊断和治疗指南 [J]. 中华风湿病学杂志, 2011, 15(6): 410-413.DOI:10.3760/cma.j.issn.1007-7480.2011.06.013.
[26] Siu YP, Leung KT, Tong MK,et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level[J].Am J Kidney Dis,2006,47(1):51-59.
[27] Momeni A, Shahidi S, Seirafian S,et al. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients[J].Iran J Kidney Dis,2010,4(2):128-132.
[28] Shibagaki Y, Ohno I, Hosoya T, et al. Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction[J].Hypertens Res,2014,37(10):919-925. DOI: 10.1038/hr.2014.107.
[29] Tsuruta Y, Mochizuki T, Moriyama T,et al. Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease[J].Clin Rheumatol,2014,33(11):1643-1648. DOI: 10.1007/s10067-014-2745-5.
相似文献/References:
[1]李雅,王志斌,刘玮晔,等.巨噬细胞与糖尿病肾病[J].国际内分泌代谢杂志,2014,(06):393.[doi:10.3760/cma.j.issn.1673-4157.2014.06.009]
Li Ya*,Wang Zhibin,Liu Weiye,et al.Macrophages and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2014,(03):393.[doi:10.3760/cma.j.issn.1673-4157.2014.06.009]
[2]王丹,关美萍,薛耀明.早期生长反应因子-1与糖尿病肾病[J].国际内分泌代谢杂志,2014,(06):397.[doi:10.3760/cma.j.issn.1673-4157.2014.06.010]
Wang Dan,Guan Meiping,Xue Yaoming..Early growth response factor-1 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2014,(03):397.[doi:10.3760/cma.j.issn.1673-4157.2014.06.010]
[3]翟丽敏,叶山东.二甲双胍的抗炎作用及其糖尿病肾脏保护作用[J].国际内分泌代谢杂志,2014,(05):334.[doi:10.3760/cma.j.issn.1673-4157.2014.05.013]
Zhai Limin,Ye Shandong..Anti-inflammatory effects of metformin and its renal protection in diabetes[J].International Journal of Endocrinology and Metabolism,2014,(03):334.[doi:10.3760/cma.j.issn.1673-4157.2014.05.013]
[4]玄先法,李清芹,王玉新,等.肾炎康复片联合缬沙坦治疗Ⅳ期糖尿病肾病蛋白尿的临床研究[J].国际内分泌代谢杂志,2014,(05):353.[doi:10.3760/cma.j.issn.1673-4157.2014.05.019]
Xuan Xianfa,Li Qingqin,Wang Yuxin,et al.Clinical study of Shenyankangfu tablet combined with valsartan capsule on proteinuria in patients with stage Ⅳ diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2014,(03):353.[doi:10.3760/cma.j.issn.1673-4157.2014.05.019]
[5]曹萌 陈堃 茅晓东 刘超.限食治疗糖尿病肾病的研究进展[J].国际内分泌代谢杂志,2015,(06):395.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.009]
Cao Meng,Chen Kun,Mao Xiaodong,et al.Effects of diet restriction on diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):395.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.009]
[6]于菁 王秋月.多聚ADP核糖聚合酶-1与糖尿病肾病[J].国际内分泌代谢杂志,2015,(06):409.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.013]
Yu Jing,Wang Qiuyue..Poly(ADP-ribose)polymerase-1 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):409.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.013]
[7]马静茹,牟新.表观遗传学与糖尿病肾病[J].国际内分泌代谢杂志,2016,36(01):52.[doi:10.3760/cma.j.issn.1673-4157.2016.01.013]
Ma Jingru*,Mou Xin..Epigenetics and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2016,36(03):52.[doi:10.3760/cma.j.issn.1673-4157.2016.01.013]
[8]杨薇,李春君,孙蓓,等.雷公藤多苷对糖尿病肾病大鼠核因子-κB
信号通路的影响[J].国际内分泌代谢杂志,2016,36(02):107.[doi:10.3760/cma.j.issn.1673-4157.2016.02.008]
Yang Wei*,Li Chunjun,Sun Bei,et al.Effects of triperygium wilfordii polyglucoside on nuclear factor-κB signaling pathway in rats with diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2016,36(03):107.[doi:10.3760/cma.j.issn.1673-4157.2016.02.008]
[9]刘艳,田秀标,韩颖,等.血管紧张素1-7与糖尿病及糖尿病肾脏
内质网应激关系的研究[J].国际内分泌代谢杂志,2016,36(03):157.[doi:10.3760/cma.j.issn.1673-4157.2016.03.04]
Liu Yan*,Tian Xiubiao,Han Ying,et al.Relationship between angiotensin 1-7, diabetes and endoplasmic reticulum stress of diabetic kidney[J].International Journal of Endocrinology and Metabolism,2016,36(03):157.[doi:10.3760/cma.j.issn.1673-4157.2016.03.04]
[10]李爱琴,林立平,王钧,等.尿脂联素与糖尿病肾病严重程度的
相关性研究[J].国际内分泌代谢杂志,2016,36(04):233.[doi:10.3760/cma.j.issn.1673-4157.2016.04.06]
Li Aiqin,Lin Liping,Wang Jun,et al.Relationship between urinary adiponectin and the severity of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2016,36(03):233.[doi:10.3760/cma.j.issn.1673-4157.2016.04.06]